Similar articles

• Effect of neuroleptic drugs on central catecholamine turnover assessed using tyrosine- and dopamine- -hydroxylase inhibitors.

  Andén NE, Corrodi H, Fuxe K. Andén NE, et al. J Pharm Pharmacol. 1972 Mar;24(3):177-82. doi: 10.1111/j.2042-7158.1972.tb08961.x. J Pharm Pharmacol. 1972. PMID: 4402775 No abstract available.
• Behavioral effects of haloperidol after tyrosine hydroxylase inhibition.

  Ahlenius S, Engel J. Ahlenius S, et al. Eur J Pharmacol. 1971 Jul;15(2):187-92. doi: 10.1016/0014-2999(71)90172-5. Eur J Pharmacol. 1971. PMID: 4403549 No abstract available.
• Comparison of the behavioral depressant effects of biogenic amine depleting and neuroleptic agents following various 6-hydroxydopamine treatments.

  Cooper BR, Grant LD, Breese GR. Cooper BR, et al. Psychopharmacologia. 1973 Jul 17;31(2):95-109. doi: 10.1007/BF00419810. Psychopharmacologia. 1973. PMID: 4722209 No abstract available.
• [Neuroleptics, monoamine oxidase inhibitors and dopamine beta hydroxylase inhibitors: their actions and interactions].

  Vetulani J. Vetulani J. Postepy Hig Med Dosw. 1973 Nov-Dec;27(6):725-80. Postepy Hig Med Dosw. 1973. PMID: 4589208 Review. Polish. No abstract available.
• Short- and long-term regulation of tyrosine hydroxylase.

  Costa E, Guidotti A, Zivkovic B. Costa E, et al. Adv Biochem Psychopharmacol. 1974;12(0):161-75. Adv Biochem Psychopharmacol. 1974. PMID: 4154019 Review. No abstract available.